Janelle D' Alvise is the Pres, CEO, Corp. Sec. & Director at Acasti Pharma Inc.
As the Pres, CEO, and Corp. Sec. & Director of Acasti Pharma Inc, the total compensation of Ms Alvise at Acasti Pharma Inc is $565,484. There are no executives at Acasti Pharma Inc getting paid more.
Ms Alvise is 65, she's been the Pres, CEO, and Corp. Sec. & Director of Acasti Pharma Inc since . There are 1 older and 6 younger executives at Acasti Pharma Inc. The oldest executive at Acasti Pharma Inc is Janelle D'Alvise, 66, who is the Pres, CEO, Corp. Sec. & Director.
Janelle's mailing address filed with the SEC is C/O ACASTI PHARMA INC., 3009 BOUL. DE LA CONCORDE, SUITE 102, LAVAL, A6, H7E 2B5.
Over the last 3 years, insiders at Acasti Pharma Inc have traded over $0 worth of Acasti Pharma Inc stock and bought 676,752 units worth $1,252,067 . The most active insiders traders include Vimal Kavuru, John Canan, and R. Loch Macdonald. On average, Acasti Pharma Inc executives and independent directors trade stock every 13 days with the average trade being worth of $785,032. The most recent stock trade was executed by Vimal Kavuru on 25 September 2023, trading 676,371 units of ACST stock currently worth $1,251,286.
acasti pharma, inc., a subsiduary of neptune technologies & bioressources, is a quebec-based biopharmaceutical dedicated in advancing a proprietary portfolio based on marine phospholipids. our products can be used in prescription, medical food and over-the-counter applications, either as a stand-alone, or, as a fixed-dose combination to exisitng productrs, for the prevention and treatment of cardiometabolic disorders.
Acasti Pharma Inc executives and other stock owners filed with the SEC include: